Vietnam is rapidly strengthening its position as an emerging destination for international clinical research, with growing investment from pharmaceutical companies, biotechnology firms and contract research organisations (CROs). As healthcare infrastructure improves and regulatory reforms gather pace, the country's clinical trial services sector is becoming an increasingly important part of the regional life sciences ecosystem.
Although no standalone valuation has been published for Vietnam's Clinical Trial Services Market, industry analysis estimates the sector is currently worth US$240–300 million in 2025 and could reach US$430–550 million by 2030.
Clinical trial services encompass the specialist activities required to design, manage and deliver clinical studies across every stage of drug and medical device development. The market includes patient recruitment, site management, regulatory affairs, monitoring, medical writing, biostatistics, data management, pharmacovigilance and central laboratory services, together with increasingly important digital technologies supporting decentralised and hybrid clinical trials.
Several structural factors are driving growth across Vietnam.
The country offers a large population of more than 100 million people, increasing prevalence of chronic diseases and a growing network of modern hospitals capable of participating in international research programmes. These advantages provide access to diverse patient populations while enabling sponsors to recruit participants more efficiently than in many mature markets.
Vietnam is also becoming more attractive as regulatory processes improve. A recent KPMG report highlights significant opportunities to simplify ethics review, strengthen government support and expand investment in clinical research. The report projects Vietnam's wider clinical trials market could reach US$749.5 million by 2029, creating thousands of highly skilled jobs while improving patient access to innovative medicines.
Digital technologies are accelerating this transformation. According to IMARC Group, Vietnam's Clinical Trial Management Systems Market reached US$5.4 million in 2025 and is forecast to grow to US$10.1 million by 2034. Artificial intelligence, machine learning and advanced analytics are increasingly being integrated into clinical trial platforms to improve patient recruitment, automate workflow management, optimise protocol design and enhance data quality.
Globally, demand for outsourced clinical development continues to rise. MarketsandMarkets estimates the Global Clinical Trial Services Market will grow from US$66.6 billion in 2025 to US$101.9 billion by 2030, driven by increasing pharmaceutical research, precision medicine, biologic drug development and greater reliance on specialist CROs.
Decentralised clinical trials are becoming one of the sector's most important developments. Remote patient monitoring, wearable medical devices, electronic informed consent and electronic source data are enabling more patient-centric studies while reducing recruitment barriers and improving participant retention. Artificial intelligence is also helping sponsors identify eligible patients, predict enrolment performance and optimise study operations through advanced analytics.
Vietnam's expanding biotechnology, pharmaceutical manufacturing and precision medicine sectors further strengthen the outlook for clinical research. Increasing collaboration between hospitals, universities and international life sciences companies is creating opportunities for Phase I-IV studies across oncology, infectious diseases, cardiovascular medicine, endocrinology and rare diseases.
Leading organisations providing clinical trial services globally include IQVIA, ICON plc, Parexel, PPD (Thermo Fisher Scientific), Syneos Health, Medpace, PSI CRO, Fortrea, SGS Life Sciences and Charles River Laboratories. These companies continue to invest in artificial intelligence, decentralised clinical trial capabilities, digital health technologies and advanced data analytics to improve trial efficiency and patient outcomes.
As Vietnam continues to modernise its healthcare system and strengthen its clinical research infrastructure, the country is well positioned to become one of Southeast Asia's leading destinations for clinical development. For pharmaceutical manufacturers, biotechnology companies, CROs, laboratory service providers, clinical technology developers and digital health innovators, Vietnam represents an increasingly attractive market with strong long-term growth potential.
